Evidence map›Paper›PMID 40872808›Full record

ReviewViruses2025

Phage Therapy: Combating Evolution of Bacterial Resistance to Phages.

Stephen T Abedon

Abstract readReview
In one paragraph

Review in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Robust detection in faeces andVeterinary and animal science · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Stephen T AbedonDepartment of Microbiology, The Ohio State University, Mansfield, OH 44906, USA.ORCID 0000-0001-9151-2375

Funding

The impact of bacteriophage therapy on wound infection dynamicsR01AI169865 · NIAID · OHIO STATE UNIVERSITY · PI Daniel J Wozniak · 2022 to 2026
$3.7M
Phage extracellular polysaccharide depolymerases to combat Pseudomonas aeruginosa biofilmsR21AI156304 · NIAID · OHIO STATE UNIVERSITY · PI ABEDON, STEPHEN T · 2021 to 2022
$429k
NIAID NIH HHS R01 AI169865NIAID NIH HHS R21 AI156304U.S. Public Health Service R01AI169865U.S. Public Health Service R21AI156304
6 · The paper itself

Abstract

Treatments for bacterial infections can be less effective due to toxicities, bacterial tolerance, or genetic resistance to antibacterial agents. The emphasis here is on combating genetic bacterial resistance to bacteriophages. Commonly described simply as phages, bacteriophages are the viruses of bacteria. As phage therapies, they are one of the oldest clinical treatments for bacterial infections. Thwarting bacterial evolution of resistance to phages, particularly during phage treatments, typically involves targeting more than one bacterial characteristic. This can be achieved serially, involving phage substitution after bacterial resistance has become problematic, something that is used especially during more personalized therapies. Substitution phages can be sourced in various ways. This includes as autophages, from phage banks, or via phage training-all as considered here-as well as through phage engineering. An alternative approach is preventing bacterial mutations from occurring at all. In addition, there is simultaneous targeting of multiple bacterial characteristics. These latter strategies include all of the following: using phages that target bacterial fitness or virulence determinants, employing individual phages that recognize multiple receptors, using phage cocktails, or applying phages in combination with antibiotics. This review discusses these different approaches for combating treatment resistance, highlighting various pros and cons.

Indexed as

BacteriaBacterial InfectionsBacteriophagesPhage TherapyAnti-Bacterial AgentsDrug Resistance, BacterialHumansAnti-Bacterial Agentsantibioticsbacteriophage therapycommunity resistancephage breedingphage libraryphage resistancephage steeringpolyphagetreatment resistance

Identifiers

PMID40872808
PMCPMC12390681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.